Milestones
MAY, Moleac Pte Ltd wins SBR National Business Award for Pharmaceuticals
OCTOBER, World Stroke Day 2020
Stroke remains one of the main cause for disability worldwide. Moleac remains committed to helping patients Reconnect with their loved ones. We always place patients at the center of everything we do, and their journey towards full recovery is what reminds us of our main purpose as a healthcare company.
OCTOBER, ESOC 2020: Abstracts on NeuroAiD
APRIL, publication of the BRAINS study. Conducted in New Zealand, the BRAINS study shows that a 6-month course of NeuroAiD improves cognitive functions in mild and moderate TBI patients.
FEBRUARY, NeuroAiD available in 5 African countries after launch in Nigeria.
OCTOBER, Moleac’s flagship product NeuroAiD™ was named Asia Pacific Neurological Disorders New Product Innovation of the Year at the Frost & Sullivan Best Practices Awards. This award recognizes healthcare products that are bringing innovative solutions for neurological disorders by pushing the boundaries of the usual practices. This award also acknowledges Moleac for its effort and continuous investment in NeuroAiD™’s Research and Development.
JUNE, Landmark Study CHIMES-E published –initial 3-month treatment with NeuroAiD help patients achieve independence with a statistically significant benefit persisting up to 18 months.
JULY, new paper “The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD)” published in the journal of Evidence-Based Medicine highlights the importance of patient selection to improve detection of a treatment effect with NeuroAiD™.
A third publication from the CHIMES Study is published in the International Journal of Stroke. This paper shows a significant favorable treatment effect of NeuroAiD™ in patient included with more predictors of poorer outcome.
NeuroAiD™ have been launched in Spain, Portugal, Morocco, Kosovo and Ivory Coast, making NeuroAiD™ available in over 30 countries!
Moleac has just turned 10 years old! During this decade, many achievements have been done especially the expansion of NeuroAiD™ distribution to 29 countries in the world.
AUGUST, the CHIMES study results on functional recovery have been published in the Stroke journal.
Primary results of the CHIMES study were published online by the Stroke Journal in June. Printed version to appear in August’s edition. Researchers found NeuroAiD™, a stroke treatment based on Traditional Chinese Medicine, increases the odds of achieving a better functional outcome.
MAY, Moleac announces the results of the CHIMES clinical trial, an investigator-initiated study of NeuroAiD™ in Stroke Recovery.
The meta-analysis on the efficacy of NeuroAiD™ in post stroke recovery was published in March as part of an entire supplement in the Cerebrovascular Diseases journal. The supplement titled ‘New Developments in Neurorestorative Therapies from Natural Substances’ compiled five papers on the pharmacology of NeuroAiD™ and included a topic on ‘Drugs from Natural Substances: Why Study Them in Cerebral Infarction’ written by renowned Neurologist, Marie-Germaine Bousser.
MAY, CHIMES trial completed patients’ inclusion, results are expected mid 2013.
Moleac announces the beneficial effect of NeuroAiD™ (MLC901) in protecting the brain against global ischemia.
JUNE, the team led by Prof. Micheal Lazdunski published a paper establishing NeuroAiD’s reparative effects on global cerebral ischemia
JANUARY, Prof Michel Lazdunski, Vice President Research of Moleac, receives Gold Medal from Jung Foundation for Science and Research for his work on ion channels.
JANUARY, a team led by Prof. Lazdunski has established the novel mechanism of action of NeuroAiD showing that it increases neurogenesis, neurites outgrowth and synaptogenesis. The team also extended the scope of research on other neurological deficit diseases.
Creation of new offices in Paris to support Moleac’s European expansion.
Launch of NeuroAiD in Iran, Iraq, Thailand and Pakistan.
Alliances with top research institutes and hospitals in China and Singapore.
Initiation of CHIMES trial to measure the efficacy of NeuroAiD when initiated at the acute stage of stroke (completion in 2012).
Long term partnership aimed at building clinical evidence in the West and supporting sales development outside of China.
Leading Key Opinion Leaders from Asia, Europe, and Australia join the CHIMES initiative.
First clinical trials for TCM derived drugs involving leading Key Opinion Leaders in Europe
Formation of Scientific Advisory Board comprising the world’s leading experts in pharmacology and molecular biology.
Alliances with top research institutes and hospitals in China and Singapore.